CD45RB-targeting strategies for promoting long-term allograft survival and preventingchronic allograft vasculopathy1
- 1 April 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 75 (8), 1142-1146
- https://doi.org/10.1097/01.tp.0000060567.48258.9d
Abstract
CD45RB is a potent immunomodulatory target to achieve long-term allograft survival. We evaluated the in vivo effect of anti-CD45RB monoclonal antibody (mAb) treatment in combination with conventional immunosuppression or costimulatory blockade strategies as a therapeutic modality for future clinical application. A fully MHC-mismatched vascularized mouse cardiac allograft model was used to test the interactions between anti-CD45RB mAb and conventional immunosuppressive drugs or costimulatory blockade of the CD40/CD154 or B7/CD28 pathway. Chronic rejection was examined histologically for development of chronic allograft vasculopathy. Cyclosporine significantly abrogated the effect of anti-CD45RB therapy. In contrast, rapamycin acted synergistically with anti-CD45RB mAb in promoting long-term allograft survival. CD154 blockade further enhanced the tolerogenic efficacy of anti-CD45RB mAb. These synergistic effects of combination treatments also prevented the development of chronic allograft vasculopathy. CD45RB-targeting strategy in combination with the use of rapamycin or costimulatory blockade promotes allograft tolerance and prevents chronic rejection.This publication has 23 references indexed in Scilit:
- New Insights Into the Interactions Between T-Cell Costimulatory Blockade and Conventional Immunosuppressive DrugsAnnals of Surgery, 2002
- LONG-TERM ALLOGRAFT ACCEPTANCE INDUCED BY SINGLE DOSE ANTI-LEUKOCYTE COMMON ANTIGEN (RT7) ANTIBODY IN THE RAT1Transplantation, 2001
- Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant ModelsThe Journal of Immunology, 2001
- CTLA-4 up-regulation plays a role in tolerance mediated by CD45Nature Immunology, 2001
- Intragraft CD45 RO gene expression is an early marker to detect small bowel allograft rejection in ratsMicrosurgery, 1999
- Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RBThe Journal of Heart and Lung Transplantation, 1999
- Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases.Journal of Molecular Medicine, 1998
- Differential Regulation of Activation-induced Tyrosine Phosphorylation and Recruitment of SLP-76 to Vav by Distinct Isoforms of the CD45 Protein-tyrosine PhosphataseOnline Journal of Public Health Informatics, 1996
- CD45: An Emerging Role as a Protein Tyrosine Phosphatase Required for Lymphocyte Activation and DevelopmentAnnual Review of Immunology, 1994
- The Role of Protein Tyrosine Kinases and Protein Tyrosine Phosphatases in T Cell Antigen Receptor Signal TransductionAnnual Review of Immunology, 1994